MaxCyte Investor Presentation Deck

2023 YTD Summary and Outlook for 2023+ ● ● 1 2023 YTD Achievements Five SPL partnerships announced year-to-date: ● Prepare/Isolate ● 2 Prime Medicine in August, Lyell Immunopharma and Vittoria Biotherapeutics in July, Walking Fish Therapeutics in May and Catamaran Bio in January The total number of SPL partners now stands at 23 Total cash, cash equivalents and short-term investments were $216 million as of June 30, 2023 Concentrate Douglas J. Swirsky appointed MaxCyte's Chief Financial Officer, bringing over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations Published Inaugural ESG 2023 Summary Report in May ● ● 21 3 2888 4 Culture 5 Cryopreserve M MaxCyte 6 Thaw/Dose 2023 Guidance and 2023+ Outlook Core revenue for 2023 expected to be comparable to 2022 and SPL Program-related revenue expected to be approximately $6 million for the year Continue to launch new PAs to address customer needs around scale and build out in-house manufacturing capacity including automation Controlled launch of the VLx to develop use cases in applications and cell types Continue to build out capabilities to serve global commercial launches of therapeutic products enabled by MaxCyte Evaluate opportunities that are an expansion of the core technology including process analytics and product characterization © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation